GlassScriptPhysician profile
Sharon James
NPI 1659385128
$1,804.28
in general payments reported to CMS, 2019-2025
12 companies · $678 in 2025
The $678 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.02 · 2023: $340 · 2024: $763 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $338.10 | 2023-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $333.74 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $286.39 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $200.99 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $195.09 | 2025 | Auvelity |
| Exact Sciences Corporation | $148.19 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $124.16 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $88.74 | 2025 | Cobenfy |
| Lundbeck LLC | $26.85 | 2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.95 | 2025 | Invega Sustenna |
| Noven Therapeutics, LLC | $18.06 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.